Form 8-K - Current report:
SEC Accession No. 0001628280-25-036846
Filing Date
2025-07-31
Accepted
2025-07-31 07:36:17
Documents
15
Period of Report
2025-07-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cbio-20250729.htm   iXBRL 8-K 34128
2 EX-10.1 exhibit-101xexecutivesever.htm EX-10.1 103488
3 EX-99.1 pressrelease-q22025.htm EX-99.1 46623
7 image_0.jpg GRAPHIC 56799
  Complete submission text file 0001628280-25-036846.txt   405909

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cbio-20250729.xsd EX-101.SCH 1800
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cbio-20250729_lab.xml EX-101.LAB 21885
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cbio-20250729_pre.xml EX-101.PRE 12520
17 EXTRACTED XBRL INSTANCE DOCUMENT cbio-20250729_htm.xml XML 2716
Mailing Address 300 FIFTH AVENUE WALTHAM MA 02451
Business Address 300 FIFTH AVENUE WALTHAM MA 02451 617-430-5595
CRESCENT BIOPHARMA, INC. (Filer) CIK: 0001253689 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36177 | Film No.: 251169449
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)